Nonmyeloablative Allogeneic Transplant

Inclusion Criteria: 1. Age \> 55 years or 2. Age \< 55 and LVEF \< 45% or creatinine clearance \< 60 ml/min 3. Ability to cover the cost of the transplant, necessary medications, and transportation/housing. 4. Caregiver must be available while outpatient Guidelines for Cladribine-Melphalan-based conditioning: * Bone Marrow Failure States Severe Aplastic Anemia (relapsed following immunosuppressive therapy) Paroxysmal Nocturnal Hemoglobinuria (poor prognostic features or hemosiderosis) * AML (first CR except for t(15;17), inv16, t(8,21); second CR; relapse failing second induction attempt) * ALL (first CR with at least one poor prognostic feature; second or greater CR; relapse failing reinduction attempt) * MDS (RAEB, RAEBiT, CMMoL) * CML (chronic phase; accelerated phase; blast phase following reinduction attempt; 2nd chronic or accelerated phase following gleevec therapy * Hodgkin's lymphoma (first or greater relapse) * Non-Hodgkin's Lymphoma * Aggressive Histology (includes T Cell NHL) Incomplete response to induction Second CR Sensitive or refractory relapse * Indolent Histology Second or greater relapse * Mantle Cell Lymphoma (any Stage - must have received induction chemotherapy) * Multiple Myeloma (10% residual plasmacytosis following anthracycline-based chemotherapy or residual disease following autologous transplant) * Waldenstrom Macroglobulinemia (must have failed either purine analogue-based chemotherapy (Fludara or 2CdA) or standard CVP therapy; hyperviscosity or cytopenias) Guidelines for total lymphoid irradiation-based conditioning * MDS (RA, RARS) * CLL (Rai stage III or IV - must have received at least two different treatment regimens in the past) * Breast Cancer (symptomatic metastatic disease, who have failed standard chemotherapy) * Renal Cell Cancer (metastatic disease at multiple sites) * Malignant Melanoma (metastatic disease at multiple sites) * Sarcoma (all subtypes presently, unresectable metastatic disease) * Ovarian Cancer (stage III or IV, platinum insensitive disease, i.e. progression within 6 months of initial platinum chemotherapy) * Thymoma (unresectable disease) Exclusion Criteria: 1. Prior allogeneic stem cell or bone marrow transplant 2. Current or past history of invasive mycotic infection 3. Breast Feeding